{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-25-000082","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.267511+00:00","generated_at":"2026-05-17T00:20:24.067508+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Gossamer Bio Q3 net loss $48.2M; PROSERA topline due Feb 2026","bullets":["Net loss of $48.2M ($0.21 per share) vs $30.8M loss a year ago; revenue from Chiesi collab $13.3M.","Cash, cash equivalents and marketable securities $180.2M; sufficient to fund ops into 2027.","PROSERA Phase 3 PAH study enrollment complete (390 pts); topline results expected February 2026.","First site activated for SERANATA Phase 3 PH-ILD study; targeting enrollment of ~480 patients.","Strategic option agreement to acquire Respira via 1.5M shares; no new trials expected before 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-25-000082","json":"https://secwatch.observer/filing/0001728117-25-000082.json","markdown":"https://secwatch.observer/filing/0001728117-25-000082.md","text":"https://secwatch.observer/filing/0001728117-25-000082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811725000082/0001728117-25-000082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811725000082/goss-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:20:24.067508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}